First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
CollPlant (NASDAQ: CLGN) said Mayo Clinic researchers developed a first‑in‑kind fully humanized 3D bioprinted human skin model using CollPlant's plant‑derived recombinant human collagen (rhCollagen) bioink, announced Oct. 16, 2025.
The model combines rhCollagen bioinks with human fibroblasts, melanocytes and keratinocytes and is integrated into a skin‑on‑a‑chip system to evaluate topical and transdermal drug delivery as a non‑animal preclinical platform. Claimed advantages include high‑throughput production, personalized human skin models at scale, reduced animal testing, and potential use in cosmetic and pharmaceutical testing, disease modeling, drug development and regenerative medicine.
CollPlant (NASDAQ: CLGN) ha detto che i ricercatori della Mayo Clinic hanno sviluppato un modello di pelle umana completamente umanizzato e stampato in 3D per bioprinting utilizzando l'inchiostro bio rhCollagen ricombinante di CollPlant, annunciato il 16 ottobre 2025.
Il modello combina bioink rhCollagen con fibroblasti umani, melanociti e cheratinociti ed è integrato in un sistema pelle-su-chip per valutare la somministrazione di farmaci topici e transdermici come piattaforma preclinica non animale. I vantaggi dichiarati includono produzione ad alta produttività, modelli di pelle umana personalizzati su larga scala, riduzione dei test sugli animali e potenziale uso in test cosmetici e farmacologici, modellazione di malattie, sviluppo di farmaci e medicina rigenerativa.
CollPlant (NASDAQ: CLGN) anunció que investigadores de Mayo Clinic desarrollaron un modelo de piel humana completamente humanizado y 3D biimpreso utilizando la tinta biológica de colágeno humano recombinante de origen vegetal rhCollagen de CollPlant, anunciado el 16 de octubre de 2025.
El modelo combina bioinks rhCollagen con fibroblastos humanos, melanocitos y queratinocitos y está integrado en un sistema piel-en-un-chip para evaluar la entrega de fármacos tópicos y transdérmicos como una plataforma preclínica no animal. Las ventajas declaradas incluyen producción de alto rendimiento, modelos de piel humana personalizados a gran escala, reducción de pruebas en animales y uso potencial en pruebas cosméticas y farmacéuticas, modelado de enfermedades, desarrollo de fármacos y medicina regenerativa.
CollPlant (NASDAQ: CLGN)는 Mayo Clinic 연구원들이 CollPlant의 식물 기반 재조합 인체 콜라겐(rhCollagen) 바이오잉크를 사용하여 전례 없는 완전히 인체화된 3D 바이오프린트 인공 피부 모델을 개발했다고 2025년 10월 16일 발표했다.
이 모델은 rhCollagen 바이오잉크를 인간 섬유아세포, 멜라노사이트, 케라티노사이트와 결합하고 피부-칩 시스템에 통합되어 국소 및 경피 약물 전달을 비동물 사전임상 플랫폼으로 평가한다. 고처리량 생산, 대규모 맞춤형 인간 피부 모델, 동물시험 감소 및 화장품 및 제약 시험, 질병 모델링, 약물 개발 및 재생의료에의 잠재적 사용 등의 이점을 포함한다.
CollPlant (NASDAQ: CLGN) a annoncé que des chercheurs de Mayo Clinic ont développé un modèle de peau humaine complètement humanisé imprimé en 3D pour la bioprint utilisant l'encre biologique rhCollagen (collagène humain recombiné d'origine végétale) de CollPlant, annoncé le 16 octobre 2025.
Le modèle combine des bioinks rhCollagen avec des fibroblastes humains, des mélanocytes et des kératinocytes et est intégré dans un système peau-sur-puce pour évaluer la délivrance topique et transdermique des médicaments comme plateforme préclinique non animale. Les avantages revendiqués incluent une production à haut débit, des modèles de peau humaine personnalisés à grande échelle, une réduction des tests sur les animaux et une utilisation potentielle dans les tests cosmétiques et pharmaceutiques, la modélisation des maladies, le développement de médicaments et la médecine régénératrice.
CollPlant (NASDAQ: CLGN) sagten Mayo Clinic-Forscher, dass sie ein erstes vollständig humanisiertes 3D-biogedrucktes Hautmodell unter Verwendung von CollPlants pflanzlich gewonnenem rekombinantem humanem Kollagen (rhCollagen) Bio-Tinte entwickelt haben, wie am 16. Oktober 2025 bekannt gegeben.
Das Modell kombiniert rhCollagen-Bio-Tinten mit menschlichen Fibroblasten, Melanozyten und Keratinozyten und ist in ein Haut-auf-einem-Chip-System integriert, um topische und transdermale Arzneimittelabgabe als eine nicht-tierische präklinische Plattform zu bewerten. Vorteilsbehauptungen umfassen eine Hochdurchsatzproduktion, maßgeschneiderte menschliche Hautmodelle in großem Maßstab, Reduzierung von Tierversuchen und potenzielle Anwendungen in Kosmetik- und Pharma-Tests, Krankheitsmodellierung, Wirkstoffentwicklung und regenerative Medizin.
CollPlant (NASDAQ: CLGN) قالت أن باحثين في Mayo Clinic طوروا نموذج جلد بشري مطبوع ثلاثي الأبعاد بشكل كامل مهيأ بشخصية بشرية فريدة باستخدام حبر rhCollagen الحيواني النباتي المستخلص من CollPlant، وفق إعلان في 16 أكتوبر 2025.
يجمع النموذج بين أحبار rhCollagen الحيوية وخلايا ليفية بشرية وخلايا صبغية وخلايا شبيهة بالكيراتين وهو مدمج في نظام جلد على رقاقة لتقييم توصيل الدواء الموضعي والعبر جلدي كمنصة قبل سريرية غير حيوانية. تشمل المزايا المعلنة الإنتاج عالي الإنتاجية، ونماذج جلد بشري مخصصة على نطاق واسع، وتقليل اختبارات الحيوانات، والاستخدام المحتمل في اختبارات العناية والتجميل والصناعات الدوائية، ونمذجة الأمراض، وتطوير الأدوية والطب التجديدي.
CollPlant (NASDAQ: CLGN) 宣布 Mayo Clinic 的研究人员开发了一种使用 CollPlant 的植物来源重组人类胶原蛋白(rhCollagen) 生物墨水的首个完全人性化的3D 生物打印人皮模型，公告日期为 2025 年 10 月 16 日。
该模型将 rhCollagen 生物墨水与人类成纤维细胞、黑色素细胞和角质形成细胞结合，并集成到皮肤芯片系统中，用于评估局部和经皮药物给药，作为非动物的前临床平台。其声称的优势包括高通量生产、可大规模定制的人皮模型、减少动物测试，以及在化妆品和制药测试、疾病建模、药物开发和再生医学中的潜在应用。
- None.
- None.
Insights
Mayo Clinic used CollPlant's plant-derived rhCollagen to create a fully humanized 3D bioprinted skin model, enabling non-animal preclinical testing.
The platform pairs CollPlant's recombinant human collagen bioinks with human fibroblasts, melanocytes and keratinocytes to recreate layered skin structure. Integration into a skin-on-a-chip permits topical and transdermal exposure studies without animals, which shortens experimental cycles and increases biological relevance for human-specific endpoints.
Key dependencies include reproducible bioink performance, validation of functional endpoints versus human tissue, and adoption by regulated laboratories. Risks include limited real-world validation and the need for regulatory and industry acceptance before replacing standard animal or human tissue tests.
Watch for peer-reviewed replication, commercial-scale bioink supply agreements, and regulatory acceptance signals over the next 6–24 months; the publication dated
- The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research.
- According to a scientific article published in the Archives of Dermatological Research, the model developed by Mayo Clinic researchers combines CollPlant's plant-derived recombinant human collagen (rhCollagen) with distinct and essential human skin cell types.
- This innovative platform offers a sustainable and ethical solution for cosmetic and pharmaceutical testing, disease modeling, and drug development.
REHOVOT,
The novel model specifically consists of CollPlant's rhCollagen-based bioinks used for 3D bioprinting and human skin fibroblasts, melanocytes and keratinocytes. The integration of these constructs into a skin-on-a-chip system enables the evaluation of topical and transdermal drug delivery in a non-animal model. In addition, the 3D bioprinting of skin using plant-derived rhCollagen presents significant advantages, including high-throughput production of personalized human skin models, and potential applications in regenerative medicine and other areas of medicine.
Yehiel Tal, Chief Executive Officer of CollPlant, commented, "We are excited about the impressive and innovative work resulting from Mayo Clinic's research and utilizing our rhCollagen technology. The model presents significant advantages, including providing a template for producing personalized human skin models at scale, enabling the reduction of animal testing, and creating learnings to apply to advancements in regenerative medicine. The results of this study further substantiate the vast potential of rhCollagen-based bioinks for use in 3D bioprinting applications including in vitro 3D models as well as in regenerative medicine."
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications within the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com.
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
+ 972-73-2325600
Eran@collplant.com
Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com
Photo: https://mma.prnewswire.com/media/2797946/Mayo_Clinic_CollPlant.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/first-in-kind-fully-humanized-3d-bioprinted-human-skin-model-developed-by-mayo-clinic-researchers-using-collplants-rhcollagen-based-bioink-302585959.html
SOURCE CollPlant
FAQ
What did CollPlant and Mayo Clinic announce on October 16, 2025 regarding CLGN?
How does the new 3D bioprinted skin model using CLGN's rhCollagen reduce animal testing?
What cell types are included in the CollPlant‑enabled 3D skin model mentioned by CLGN?
What applications does the Mayo Clinic 3D skin model using CLGN's rhCollagen target?
Does the CollPlant rhCollagen 3D skin model enable personalized testing for CLGN partners?
Will the CLGN‑based skin model be used for topical and transdermal drug delivery testing?
